Metastatic bladder cancer: new insights into tumour spread and chemotherapy resistance

Hartwig data supports new Nature study on lethal metastatic bladder cancer. Researchers used the Hartwig Medical Database to independently validate a DNA repair mechanism that appears to prevent chemotherapy from effectively treating an aggressive bladder cancer subtype.

A new study published in Nature has mapped how lethal metastatic bladder cancer evolves and spreads, enabled by the rapid autopsy programme at Fred Hutchinson Cancer Center and the University of Washington. The researchers profiled 8 primary tumors and 80 metastases from 20 patients with terminal disease and studied what contributed to their treatment outcomes.

Plasmacytoid urothelial carcinoma and resistance to platinum chemotherapy

One of the study’s central findings concerns plasmacytoid urothelial carcinoma, an aggressive subtype that shows a low burden of “platinum associated mutational scarring” compared to conventional disease.

DNA repair pathway linked to chemotherapy resistance in bladder cancer

The authors traced this to a known DNA repair pathway (also involved in Fanconi anaemia) and confirmed in cell models that activating this pathway can lead to drug resistance.

Hartwig data links DNA repair to platinum chemotherapy response

To test whether the relationship held beyond their own (small) autopsy cohort, they turned to the Hartwig Medical Database. The metastatic urothelial carcinoma data requested included whole genome sequencing linked to real world treatment records. In the data, the researchers found the same inverse correlation between DNA repair pathway activity and platinum activity (as measured by DNA scarring) in cisplatin treated patients, confirming their findings.

What terminal bladder cancer research reveals about treatment response

This study shows that even though deeply characterized cohorts of terminal disease are small, they can be highly valuable for in-depth insights. Their findings became more actionable when checked against a large uniformly processed resource.

Potential impact for Dutch patients with metastatic bladder cancer

Hartwig’s data turned a mechanism observed in twenty patients into a hypothesis worth pursuing for patients receiving platinum chemotherapy for metastatic urothelial cancer. Even for this rare cancer, this could impact about 100 patients each year in the Netherlands according to Dutch National Cancer Registry statistics.

Relevant publications and datasets

Reference: Itagi, P., Schuster, S. L. et al. Evolution and heterogeneity of lethal metastatic bladder cancer subtypes. Nature (2026). https://doi.org/10.1038/s41586-026-11035-z

Hartwig cohort as described in: NakaumaGonzález, J. A. et al. Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma. Eur. Urol. 81, 331–336 (2022).

IKNLled publication on therapy usage for Metastatic Urothelial Carcinoma of the Bladder.

You read an article in the category DNA. You may also be interested in Hartwig Medical Database, Learning healthcare system, Molecular diagnostics, Personalized treatment or Research.
All news